Hospital mortality rate is considered one of the convincing criteria to assess the efficacy of the treatment for ST-elevation myocardial infarction (STEMI). Among the predictors of the mortality risk (MR), the age over 75 years is the most significant one. The aim of the study was to comparatively assess the treatment efficacy in patients with recurrent STEMI considering the hospital mortality with regard to the baseline MR and/or the age over 75 years in different timeframes in the period from 2008 to 2017. We studied 743 patients with recurrent STEMI admitted at our Institute clinic in the period from 2008 to 2017. The first group consisted of 312 patients hospitalized from 2008 to 2011; 51 of them were over 75 years old. PCI was performed in 71 and 51 cases in the first 12 and 12–72 hours, respectively. The second group included 157 patients who were admitted in the period from 2012 to 2014; 40 of them were over 75 years old, early and delayed PCIs were performed in 57 and 32 patients, respectively. And the third group consisted of 263 patients admitted from 2015 to 2017, among whom 128 patients were over 75 years old; early and delayed PCIs were performed to 82 and 80 patients, respectively. Baseline MR was determined by TIMI. Over 10 years, the number of primary PCIs had increased from 39 % in the first period to 62 % in the third one, and from 3 % to 32 % in patients older than 75 years old. The use of delayed PCI had doubled their total number. Meanwhile, although the angiographic success rate remained unchanged, there was no decrease in hospital mortality. The explanation for this lies in the increased proportion of the hospitalized patients over 75 years of age and higher mortality rates compared to those younger 75 years of age. So, in the older age group, the baseline MR was scored 7.5 or made 25 % by TIMI, the mortality was 18.3 %, making 11.6 % and 25.2 % when the PCI performance and non-performance were taken into account. These figures were 2 times lower among patients younger 75 years of age: initial MR was scored 5 making 12.5 % by TIMI; mortality was 9.6 %, making 6.5 % and 12.5 % for PCI and non-PCI cases, respectively. In this regard, with an increase in the number of hospitalized patients over 75 years of age, a higher number of PCIs performed, which was considered as associated with an increased treatment efficacy, may have not been accompanied by a decrease in hospital mortality. With similar evaluated parameters, the treatment efficacy turns to be higher among the patients with higher MR. The mortality reduction proportional to the baseline MR in different age groups indicates the results of interventions that are similar in their efficacy. These data indicate that the hospital mortality assessment with taking into account the baseline MR and/or age over 75 years, makes it possible to assess the efficacy of treatment for STEMI more objectively, to outline the ways for increasing its efficacy by using PCI in late admission, similar to that in early procedures used without age restrictions.

BACKGROUND Fractures of the proximal humerus are more common in older adults. Two options for surgical treatment of the same fractures are routinely performed — primary arthroplasty and osteosynthesis with metal fixators. Both methods are most effective in elderly patients for augmentation of the proximal humerus. For this purpose, methyl methacrylate cement or bone allo-/autografts are used. However, the incidence of unsatisfactory functional results after surgery remains high.AIM OF STUDY To develop allogeneic graft to strengthen the proximal humerus in the osteosynthesis of a comminuted fracture with a lack of bone tissue which has osteoconductive properties and capable of being a carrier of biologically active substances.MATERIAl AND METHODS The head, neck and portion of diaphysis of a fibula of a cadaver were used for a graft. The graft 6–8 cm long was formed and saturated with a collagen solution. Ten patients with 4-fragment fractures of the proximal humerus underwent surgery. X-rays and computed tomography of the operated joint were performed the day after surgery, and then, 6 weeks, 6 months, and one year after the surgery. The follow-up period ranged from 6 to 18 months.RESUlTS When evaluating osteoconductive effect in cell culture during saturation with collagen, the content cells on the surface of bone was 5–8 thousand/cm2 and 16–18 thousand/cm2 on the sample, saturated with plasma and growth factors. The studied bone grafts were biocompatible and non-toxic for fibroblast culture. On the surface of the bone graft without collagen adhesion of minimum number of cells occurred. After saturation of the graft with collagen, the adhesive activity of cells on the bone matrix increased, which indicated the presence of an osteoconductive effect. The addition of plasma saturated with growth factors promoted an increase in the number of adhered cells; therefore, the graft can be used as a carrier of biologically active substances. Postoperative X-ray didn’t reveal secondary varus displacement of the head in any patient (except for ununiformed fracture case).CONClUSION The developed graft is non-toxic, does not possess immunogenicity, has more pronounced osteoconductive properties in comparison with native bone allografts, which contributes to its colonization with cells. The use of such a graft in clinical practice makes it possible to achieve healing of the fracture and prevent secondary displacement of fragments.

Авторы описывают морфологические и клинические особенности опухолей каротидного гломуса, представлен опыт лечения больной с длительно существовавшей хемодектомой.

No abstract